Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

• Barbieri CE, Tang LJ, Brown KA, Pietenpol JA . (2006). Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66: 7589–7597.

  Article  CAS  Google Scholar 

• Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O et al. (2003). Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem 278: 10546–10555.

  Article  CAS  Google Scholar 

• Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G et al. (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3: 387–402.

  Article  CAS  Google Scholar 

• Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X . (2004). ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 24: 1341–1350.

  Article  CAS  Google Scholar 

• Brunner HG, Hamel BC, Bokhoven HvH . (2002). P63 gene mutations and human developmental syndromes. Am J Med Genet 112: 284–290.

  Article  Google Scholar 

• Chipuk JE, Green DR . (2006). Dissecting p53-dependent apoptosis. Cell Death Differ 13: 994–1002.

  Article  CAS  Google Scholar 

• Cho Y, Gorina S, Jeffrey PD, Pavletich NP . (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.

  Article  CAS  Google Scholar 

• Davison TS, Vagner C, Kaghad M, Ayed A, Caput D, Arrowsmith CH . (1999). p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J Biol Chem 274: 18709–18714.

  Article  CAS  Google Scholar 

• Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. (2006). Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191–202.

  Article  CAS  Google Scholar 

• Di Como CJ, Gaiddon C, Prives C . (1999). p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19: 1438–1449.

  Article  CAS  Google Scholar 

• Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363–373.

  Article  CAS  Google Scholar 

• Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F et al. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560–564.

  Article  CAS  Google Scholar 

• Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . (2001). A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874–1887.

  Article  CAS  Google Scholar 

• Gannon JV, Greaves R, Iggo R, Lane DP . (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595–1602.

  Article  CAS  Google Scholar 

• Gorina S, Pavletich NP . (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274: 1001–1005.

  Article  CAS  Google Scholar 

• Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H et al. (2005). TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458–2471.

  Article  CAS  Google Scholar 

• Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE et al. (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 97: 5462–5467.

  Article  CAS  Google Scholar 

• Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG . (2003). Chemosensitivity linked to p73 function. Cancer Cell 3: 403–410.

  Article  CAS  Google Scholar 

• Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809–819.

  Article  CAS  Google Scholar 

• Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119: 861–872.

  Article  CAS  Google Scholar 

• Lanza M, Marinari B, Papoutsaki M, Giustizieri ML, D'Alessandra Y, Chimenti S et al. (2006). Cross-talks in the p53 family: DeltaNp63 is an anti-apoptotic target for DeltaNp73alpha and p53 gain-of-function mutants. Cell Cycle 5.

  Article  CAS  Google Scholar 

• Laptenko O, Prives C . (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13: 951–961.

  Article  CAS  Google Scholar 

• Lokshin M, Li Y, Gaiddon C, Prives C . (2007). p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Res 35: 340–352.

  Article  CAS  Google Scholar 

• Lokshin M, Tanaka T, Prives C . (2005). Transcriptional regulation by p53 and p73. Cold Spring Harb Symp Quant Biol 70: 121–128.

  Article  CAS  Google Scholar 

• Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25: 47–54.

  Article  CAS  Google Scholar 

• Murray-Zmijewski F, Lane DP, Bourdon JC . (2006). p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13: 962–972.

  Article  CAS  Google Scholar 

• Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119: 847–860.

  Article  CAS  Google Scholar 

• Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I et al. (1998). Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4: 839–843.

  Article  CAS  Google Scholar 

• Resnick MA, Inga A . (2003). Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100: 9934–9939.

  Article  CAS  Google Scholar 

• Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW . (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45–56.

  Article  CAS  Google Scholar 

• Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. (2001). ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781–794.

  Article  CAS  Google Scholar 

• Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A et al. (2002). Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277: 18817–18826.

  Article  CAS  Google Scholar 

• Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A et al. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276: 15164–15173.

  Article  CAS  Google Scholar 

• Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L et al. (2000). Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503–29512.

  Article  CAS  Google Scholar 

• Urist M, Tanaka T, Poyurovsky MV, Prives C . (2004). p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18: 3041–3054.

  Article  CAS  Google Scholar 

• van Bokhoven H, Brunner HG . (2002). Splitting p63. Am J Hum Genet 71: 1–13.

  Article  CAS  Google Scholar 

• Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.

  Article  CAS  Google Scholar 

• Vousden KH, Lu X . (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594–604.

  Article  CAS  Google Scholar 

• Willis AC, Pipes T, Zhu J, Chen X . (2003). p73 can suppress the proliferation of cells that express mutant p53. Oncogene 22: 5481–5495.

  Article  CAS  Google Scholar 

• Wiman KG . (2006). Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13: 921–926.

  Article  CAS  Google Scholar 

• Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR . (1999). Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci USA 96: 8438–8442.

  Article  CAS  Google Scholar 

• Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC et al. (2003). DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 63: 2351–2357.

  CAS  PubMed  Google Scholar 

• Yang A, Kaghad M, Caput D, McKeon F . (2002). On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 18: 90–95.

  Article  Google Scholar 

• Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305–316.

  Article  CAS  Google Scholar 

• Zeng SX, Dai MS, Keller DM, Lu H . (2002). SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 21: 5487–5497.

  Article  CAS  Google Scholar 

Download references